乐观
$26.69
情景价格
$38.610
+1.355 (+3.51%)收盘时
BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the cell and gene therapy market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal closed systems are purpose-built rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company's ThawSTAR product line comprises a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
BioLife Solutions Inc is currently not a strong buy due to recent downgrades and insider selling, despite a significant year-to-date increase of 56.13%.
Benchmark
—
2026-08-10
Benchmark
2026-08-10
目标价
—
Jefferies
$31
2026-07-23
Jefferies
2026-07-23
目标价
$31
H.C. Wainwright
$31
2026-07-23
H.C. Wainwright
2026-07-23
目标价
$31
TD Cowen
$31
2026-07-22
TD Cowen
2026-07-22
目标价
$31
Craig-Hallum
$31
2026-07-22
Craig-Hallum
2026-07-22
目标价
$31
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Freshworks Joins S&P SmallCap 600 Index

Biotech Stocks Reach 52-Week Highs Driven by Key Catalysts

Investor Rights Law Firm Investigates Multiple Companies for Potential Violations

Biotech Stocks Reach 52-Week Highs Driven by Key Catalysts

Investor Rights Law Firm Investigates Multiple Companies
BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the cell and gene therapy market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal closed systems are purpose-built rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company's ThawSTAR product line comprises a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).
BioLife Solutions Inc is currently not a strong buy due to recent downgrades and insider selling, despite a significant year-to-date increase of 56.13%.
3 analysts cover BLFS: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 33.25.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。